The first generation of CAR-modified T cells have shown success in pre-clinical trials and have entered phase I clinical trials in ovarian cancer, neuroblastoma and various types of leukemia and lymphoma.
The first generation of CAR-modified T cell showed success in pre-clinical trials and has entered phase I clinical trials. Clinical trials have commenced in ovarian cancer, neuroblastoma and various types of leukemia and lymphoma.